Study identifies new proteins linked to dementia risk 25 years later

AdobeCanwepredicttheriskofdementiadecadesbeforeonset?InastudypublishedinScienceTranslationalMedicine SammyKimballforSTATCanNovavaxfinallygetitright?What’sa“triple-G”drug?AndisNovoNordisklosingground?We




knowledge

author：fashion    Page View：26
Adobe

LONDON — GSK said Tuesday it would purchase the asthma-focused drug developer Aiolos Bio for $1 billion upfront, the latest in a string of pharma acquisitions that are bolstering hopes for the industry’s year ahead.

The deal includes up to another $400 million in payments if certain milestones are met.

advertisement

Aiolos was launched just last year, based in both San Francisco and London. The company, which announced a $245 million Series A round in October, has been readying a Phase 2 trial of its candidate AIO-001 in adult asthma.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In
Previous article： 7 more heat
Next article： As demand for Covid shots wanes, Moderna seeks its next success